Plain-English translation of NCT06140524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a new medication called can help people who have early warning signs of multiple myeloma—a blood cancer. Right now, these patients have abnormal plasma cells (a type of white blood cell) that may eventually develop into full-blown myeloma, but haven't yet. The trial will check if this medication can eliminate those abnormal cells before they become cancer.
People with early precancerous blood conditions like MGUS and smoldering myeloma have a moderate risk (3 to 10% per year) of developing full multiple myeloma, but doctors currently have few treatment options to stop this progression. This study aims to see if this medication can intercept the disease early and prevent it from becoming active myeloma.
You likely qualify if…
You likely don't qualify if…
The trial has two main parts: first, a small safety phase to make sure the medication is safe at different doses, and then a larger expansion phase where you'll be randomly assigned to receive one of four different dosing schedules of the medication. You'll receive the treatment over time and have regular visits for blood tests, physical exams, and monitoring to see how well the medication works and what side effects you may experience.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States